I communicated with Joe a bit yesterday. I believ
Post# of 36537
(Total Views: 371)
Posted On: 12/09/2020 12:49:47 PM
Re: Zolis_onkel #24327
I communicated with Joe a bit yesterday. I believe the delay in the announcement on the testing is this (partly Joe's input and partly my interpretation):
1) The data has been in peer review for some time.
2) Moving forward with any sort of announcement before the peer review is complete would remove most/all of the benefit of a positive peer review.
3) As a microcap company, GNBT cannot afford to move forward without an airtight peer review.
4) So we will wait until that peer review is complete. I have no estimate on when that is.
As far as NGIO goes, here again is the amalgamation of what I can find out and what I interpret:
1) The high-level valuation is due any time, and has taken a while due to the changing/developing nature of many things NGIO.
2) A more detailed valuation will follow a couple of weeks after that.
3) The IPO won't happen this year, as we will be too close to the holidays. Maybe the first week of January remains slow and the road show hits mid-Jan w listing as early as the last week of Jan?
4) We need $4/sh. Based on the valuation, Joe will adjust the share quantity if necessary to make sure that value can be achieved.
5) If the shares IPO w the full amount of 400MM shares, and maintains interest, a 20% share sale will give Joe more value to play with, and ample capital to move forward.
6) If the shares IPO w some quantity of the 400MM shares retired to achieve the $4/sh, Joe will still get 3-digit $MM in capital from a ~20% sale, and our div holdings will amount to a larger % ownership in the company, since they are a fixed quantity.
7) The more opportunities being analyzed for the NGIO valuation, the more likely an effective valuation can be reached. If you have multiple multi-billion $ opportunities, and you apply even a small success factor to each of them, you have an increased chance of actual value that the market can take interest in.
Overall, I feel very impatient. But I recognize that, despite time-frame slips, failures (whatever anyone prefers to call them), none of our opportunities has really disappeared since the Veneto mess. AltuCell is still here. Excellagen is primed and ready to run in a non-pandemic environment. NuGenHealth is ramping up (Hoping for a positive PR on those first 5k patient enrollments in the next month or so!!!). All the AZ opportunities are still dormant and waiting for capital. The Regentys products are ready for testing once capital is available. There will be a surge in non-emergency surgeries post-pandemic that will be a perfect wave to ramp up the various device kits. There will always be a need for testing. So on and so on.
There is so much here. We've been on life support, but we're still alive.
I will continue to muster patience and wait for the pieces to come together.
1) The data has been in peer review for some time.
2) Moving forward with any sort of announcement before the peer review is complete would remove most/all of the benefit of a positive peer review.
3) As a microcap company, GNBT cannot afford to move forward without an airtight peer review.
4) So we will wait until that peer review is complete. I have no estimate on when that is.
As far as NGIO goes, here again is the amalgamation of what I can find out and what I interpret:
1) The high-level valuation is due any time, and has taken a while due to the changing/developing nature of many things NGIO.
2) A more detailed valuation will follow a couple of weeks after that.
3) The IPO won't happen this year, as we will be too close to the holidays. Maybe the first week of January remains slow and the road show hits mid-Jan w listing as early as the last week of Jan?
4) We need $4/sh. Based on the valuation, Joe will adjust the share quantity if necessary to make sure that value can be achieved.
5) If the shares IPO w the full amount of 400MM shares, and maintains interest, a 20% share sale will give Joe more value to play with, and ample capital to move forward.
6) If the shares IPO w some quantity of the 400MM shares retired to achieve the $4/sh, Joe will still get 3-digit $MM in capital from a ~20% sale, and our div holdings will amount to a larger % ownership in the company, since they are a fixed quantity.
7) The more opportunities being analyzed for the NGIO valuation, the more likely an effective valuation can be reached. If you have multiple multi-billion $ opportunities, and you apply even a small success factor to each of them, you have an increased chance of actual value that the market can take interest in.
Overall, I feel very impatient. But I recognize that, despite time-frame slips, failures (whatever anyone prefers to call them), none of our opportunities has really disappeared since the Veneto mess. AltuCell is still here. Excellagen is primed and ready to run in a non-pandemic environment. NuGenHealth is ramping up (Hoping for a positive PR on those first 5k patient enrollments in the next month or so!!!). All the AZ opportunities are still dormant and waiting for capital. The Regentys products are ready for testing once capital is available. There will be a surge in non-emergency surgeries post-pandemic that will be a perfect wave to ramp up the various device kits. There will always be a need for testing. So on and so on.
There is so much here. We've been on life support, but we're still alive.
I will continue to muster patience and wait for the pieces to come together.
(11)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼